Press release
Clostridium Difficile Infections Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Clostridium Difficile Infections pipeline constitutes 20+ key companies continuously working towards developing 22+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Clostridium Difficile Infections Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Clostridium Difficile Infections Market.
The Clostridium Difficile Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Clostridium Difficile Infections Pipeline Report: https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Clostridium Difficile Infections treatment therapies with a considerable amount of success over the years.
• Clostridium Difficile Infections companies working in the treatment market are Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others, are developing therapies for the Clostridium Difficile Infections treatment
• Emerging Clostridium Difficile Infections therapies in the different phases of clinical trials are- ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others are expected to have a significant impact on the Clostridium Difficile Infections market in the coming years.
• In April 2025, Lumen Bioscience shared top-line findings from the sentinel cohort of its RePreve Clinical Trial assessing LMN-201 for Clostridioides difficile infection (CDI). LMN-201 is an oral biologic combination therapy, provided in capsule form, designed to be administered alongside and after antibiotics to enhance clinical outcomes in CDI. The therapy is developed using Lumen's proprietary spirulina-based GMP manufacturing platform.
• In February 2025, Microbiotica presented new insights into the mechanism of action of MB097 at the American Association for Cancer Research (AACR) Immuno-Oncology conference held in Los Angeles from February 23-26. MB097, a live biotherapeutic product (LBP), is being developed to complement immuno-oncology treatments, including MSD's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
• In January 2025, Vedanta Biosciences, a late clinical-stage biotechnology company focused on developing defined bacterial consortia as oral therapies for gastrointestinal disorders, announced the publication of further findings from its Phase II CONSORTIUM trial of its lead candidate, VE303, aimed at preventing recurrent *Clostridioides difficile* infection (rCDI). The latest analyses were published this month in Nature Medicine and are accessible online
• In January 2025, MaaT Pharma revealed the topline results from ARES, a key European Phase 3 multicenter trial. This single-arm, open-label study assessed the efficacy and safety of MaaT013 in patients with acute gastrointestinal Graft-versus-Host Disease (GI-aGvHD). The trial focused on third-line treatment for patients who were steroid-resistant and either refractory or intolerant to ruxolitinib.
• In January 2025, PureTech Health plc announced that Vedanta Biosciences, a company it founded, has published new results from the Phase 2 CONSORTIUM study on VE303, its leading candidate under evaluation for preventing recurrent Clostridioides difficile infection (rCDI).
• In January 2025, Seres Therapeutics, Inc. revealed new translational biomarker findings from exploratory endpoints in its Phase 1b placebo-controlled SER-155 trial with patients receiving allogeneic stem cell transplantation (allo-HSCT).
Clostridium Difficile Infections Overview
Clostridium difficile infection (CDI) is a bacterial infection that affects the colon, caused by the Clostridium difficile (C. diff) bacterium. It often occurs after the use of antibiotics, which disrupt the normal gut flora, allowing C. difficile to grow and produce toxins. Symptoms range from mild diarrhea to severe colitis and can include abdominal pain, fever, and nausea. CDI is most common in hospitalized or elderly patients and can be life-threatening if not treated. Recurrent infections are also a major concern. Treatment typically involves stopping the causative antibiotic and administering specific antibiotics like vancomycin or fidaxomicin.
Get a Free Sample PDF Report to know more about Clostridium Difficile Infections Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Clostridium Difficile Infections Drugs Under Different Phases of Clinical Development Include:
• ADS024: Adiso Therapeutics
• DNV3837: Deinove
• Ibezapolstat: Acurx Pharmaceuticals, Inc
• LMN-201:Lumen Bioscience, Inc
• Ridinilazole: Summit Therapeutics
• CP101: Finch Therapeutics Group
• SER 109: Seres Therapeutics
• VE303: Vedanta Biosciences
• MGB-BP-3: MGB Biopharma
• CRS3123: Replidyne
Clostridium Difficile Infections Route of Administration
Clostridium Difficile Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Clostridium Difficile Infections Molecule Type
Clostridium Difficile Infections Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Clostridium Difficile Infections Pipeline Therapeutics Assessment
• Clostridium Difficile Infections Assessment by Product Type
• Clostridium Difficile Infections By Stage and Product Type
• Clostridium Difficile Infections Assessment by Route of Administration
• Clostridium Difficile Infections By Stage and Route of Administration
• Clostridium Difficile Infections Assessment by Molecule Type
• Clostridium Difficile Infections by Stage and Molecule Type
DelveInsight's Clostridium Difficile Infections Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Clostridium Difficile Infections product details are provided in the report. Download the Clostridium Difficile Infections pipeline report to learn more about the emerging Clostridium Difficile Infections therapies
https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Clostridium Difficile Infections Therapeutics Market include:
Key companies developing therapies for Clostridium Difficile Infections are - Novartis AG, Astellas Pharma, Eli Lily & Company AstraZeneca, Actelion Pharmaceuticals Ltd., Merck & Co. Inc., Baxter International Inc., Sanofi S.A, Pfizer Inc., Mylan N.V, and others.
Clostridium Difficile Infections Pipeline Analysis:
The Clostridium Difficile Infections pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Clostridium Difficile Infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Clostridium Difficile Infections Treatment.
• Clostridium Difficile Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Clostridium Difficile Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Clostridium Difficile Infections market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Clostridium Difficile Infections drugs and therapies
https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Clostridium Difficile Infections Pipeline Market Drivers
• Increasing cases of Clostridium Difficile Infections, increasing consumption of antibiotics are some of the important factors that are fueling the Clostridium Difficile Infections Market.
Clostridium Difficile Infections Pipeline Market Barriers
• However, lack of awareness of the infection, high cost of the diagnostic and treatment of severe infection and other factors are creating obstacles in the Clostridium Difficile Infections Market growth.
Scope of Clostridium Difficile Infections Pipeline Drug Insight
• Coverage: Global
• Key Clostridium Difficile Infections Companies: Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others
• Key Clostridium Difficile Infections Therapies: ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others
• Clostridium Difficile Infections Therapeutic Assessment: Clostridium Difficile Infections current marketed and Clostridium Difficile Infections emerging therapies
• Clostridium Difficile Infections Market Dynamics: Clostridium Difficile Infections market drivers and Clostridium Difficile Infections market barriers
Request for Sample PDF Report for Clostridium Difficile Infections Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Clostridium Difficile Infections Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight here
News-ID: 4165743 • Views: …
More Releases from DelveInsight Business Research

Hypertrophic Cardiomyopathy Pipeline 2025: Latest FDA Approvals, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypertrophic Cardiomyopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypertrophic Cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypertrophic Cardiomyopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertrophic Cardiomyopathy Market.
The Hypertrophic…

Radioligand Therapies Market Dynamics Indicate Upward Trajectory Through 2034, R …
DelveInsight's "Radioligand Therapies Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Radioligand Therapies, historical and forecasted epidemiology as well as the Radioligand Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Radioligand Therapies, offering comprehensive insights into the Radioligand Therapies revenue trends, prevalence, and treatment landscape. The…

DUB Inhibitors Pipeline 2025: Comprehensive Clinical Trials and Therapies Analys …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, DUB Inhibitors pipeline constitutes key companies continuously working towards developing DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"DUB Inhibitors Pipeline Insight" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market.
The DUB Inhibitors Pipeline report…

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
More Releases for Clostridium
Veterinary Clostridium Vaccine Market
The veterinary clostridium vaccine market plays a crucial role in the prevention of clostridial diseases in livestock and companion animals. Clostridial infections, caused by bacteria from the Clostridium genus, can lead to severe health issues and significant economic losses in the agriculture sector. Vaccination is one of the most effective methods to control these infections, which include conditions like enterotoxemia, tetanus, and gas gangrene. The growing awareness of animal health,…
Clostridium Diagnostics Market Analysis, Size, Share & Trends | 2031
In recent years, the global Clostridium Diagnostics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Clostridium Diagnostics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Clostridium Diagnostics Market to Witness Astonishing Growth by 2030
Clostridium Diagnostics market is projected to grow at a CAGR of 7.5% from 2024 to 2030. The growth in this market can be attributed to the increasing incidence of Clostridium-related diseases, rising demand for accurate and rapid diagnosis, and growing awareness about Clostridial infections. Important changes in the business allow key players to attain larger profits. This Clostridium Diagnostics Market study report is the best way to make changes with…
Clostridium Diagnostics Market - Empowering Precision, Defeating Infection: Adva …
Newark, New Castle, USA - new report, titled Clostridium Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Clostridium Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Clostridium Diagnostics market. The report offers an overview of the market, which…
Clostridium Vaccine Market Size, Price, Share | Forecast to 2027
Latest Updated Report 2023, The Global Clostridium Vaccine Market to Growing A CAGR of % during forecast period of 2023-2027. The Market is segmented by Global Clostridium Vaccine Market Breakdown by Application (Veterinary Clinic, Veterinary Hospital) by Type (General Type) and by Geography (North America, South America, Europe, Asia Pacific, MEA).
The Clostridium Vaccine Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It…
Global Clostridium Difficile Immunoassays Market - Opportunities & Forecasts, 20 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global clostridium difficile immunoassays market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…